Previously, this case was reported regarding safety of Vemurafenib in end stage renal failure [8] and the same case was followed-up for 36 months and showed a sustained complete response even after stopping the BRAF inhibitor treatment. The gene discussed is BRAF; the disease is stage 5 chronic kidney disease.